Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $12.85M fell 22.7% year over year, behind the +44.5% change in trailing-twelve-month gross profit. Sequentially, it fell 24.4% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Gross profit amounted to 76.5% of revenue in FY2025, down 5.8 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -22.7% toward the trailing-twelve-month pace of +44.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 51.75M USD
- Year-over-year change
- +8.7%
- 4-year CAGR
- +18.6%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.75M | +8.7% |
| FY2024 | 2024-12-31 | 47.59M | +74.3% |
| FY2023 | 2023-12-31 | 27.3M | -38.7% |
| FY2022 | 2022-12-31 | 44.55M | +70.3% |
| FY2021 | 2021-12-31 | 26.16M | — |
Gross Profit vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 gross profit of -$101.61M is the 9th highest of the 10 companies compared; the peer median is $9.26M.
- Its year-over-year change of +44.5% is the 6th highest of 9, against a peer median of +111.5%.
- Gross profit amounts to 153.7% of revenue for NTLA, versus a peer median of 89.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $156.04M | +158.9% | — | 100.0% | |
| LTM Jun 2026 | $76.77M | +9554.2% | -44.1% | 89.6% | |
| LTM Mar 2026 | $73.09M | +682.6% | +68.8% | 91.6% | |
| LTM Mar 2026 | $13.42M | +23.0% | -48.1% | 74.1% | |
| LTM Mar 2026 | $9.26M | +117.7% | -9.7% | 82.6% | |
| LTM Mar 2026 | $2.25M | +105.3% | +44.7% | 5.8% | |
| LTM Mar 2026 | -$2.15M | +8.3% | — | — | |
| LTM Mar 2026 | -$2.39M | — | — | — | |
| LTM Mar 2026 | -$101.61M | +44.5% | +5.1% | 153.7% | |
| LTM Sep 2026 | -$140.69M | -4.7% | — | 558.9% | |
| Peer median (excluding NTLA) | $9.26M | +111.5% | -9.7% | 89.6% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.